Cardinal Health Lifts Dividend, but Risks Remain

What happened

Cardinal Health announced a quarterly dividend increase to $0.5158 per share, payable July 15, 2026, continuing its capital return program amid raised fiscal 2026 guidance. The hike signals management confidence but does not address structural concerns: leverage has risen with $5.3B in acquisitions, GAAP EPS ($6.45) lags non-GAAP ($8.24) by a wide margin, and CVS Health accounts for ~30% of revenue. The DeepValue master report rates CAH a Potential Sell with a base case of $205 and conviction 4.0, citing that current multiples (~22x forward P/E) embed sustained double-digit EPS growth vulnerable to policy or integration missteps. The dividend move offers little cushion for downside scenarios where specialty margins compress or a large contract is lost.

Implication

While the dividend increase reflects management's confidence in free cash flow, it does not close the gap between GAAP and non-GAAP earnings or reduce exposure to CVS concentration and IRA policy risk. At ~22x forward P/E and net debt/EBITDA of 1.76x, the stock prices in flawless execution. The base case target of $205 implies ~4% downside, while the bear case of $165 suggests ~23% risk. Investors should maintain small positions, trim above $210–$230, and watch for Q2 FY26 results and any CVS contract or IRA-related disclosures.

Thesis delta

The dividend increase is consistent with management's confident messaging but does not alter the fundamental thesis. The stock remains priced for perfection, and the dividend hike does not mitigate the key risks of integration execution, CVS concentration, and IRA policy pressure. The potential sell rating and trim-above-$235 guidance stand unchanged.